Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 7 (July)

1. Factors for satisfaction among providers of ancillary health services in a community-based cancer prevention program: a pilot study in Nevada.
   ScientificWorldJournal, 6: 727-33. [Abstract] [Full-text]
2. Breast cancer as a second primary in patients with prostate cancer--estrogen treatment or association with family history of cancer?
   J Urol, 176(2): 538-43. [Abstract] [Full-text]
3. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis.
   CMAJ, 175(1): 34-41. [Abstract] [Full-text]
4. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
   J Natl Cancer Inst, 98(13): 911-9. [Abstract] [Full-text]
5. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
   J Natl Cancer Inst, 98(13): 904-10. [Abstract] [Full-text]
6. Influence of menopausal status and use of hormone replacement therapy on radiation dose from mammography in routine breast screening.
   Br J Radiol, 79(943): 597-602. [Abstract] [Full-text]
7. Potential use of humanized antibodies in the treatment of breast cancer.
   Expert Rev Anticancer Ther, 6(7): 1065-74. [Abstract] [Full-text]
8. CSF levels of growth factors and plasminogen activators in leptomeningeal metastases.
   Neurology, 67(1): 114-9. [Abstract] [Full-text]
9. p73-dependent induction of 14-3-3sigma increases the chemo-sensitivity of drug-resistant human breast cancers.
   Biochem Biophys Res Commun, 347(1): 327-33. [Abstract] [Full-text]
10. Adult weight change and risk of postmenopausal breast cancer.
    JAMA, 296(2): 193-201. [Abstract] [Full-text]
11. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
    N Engl J Med, 355(2): 125-37. [Abstract] [Full-text]
12. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
    J Pharmacol Exp Ther, 318(2): 503-12. [Abstract] [Full-text]
13. Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells.
    Endocrinology, 147(8): 3843-50. [Abstract] [Full-text]
14. Ovarian cancer metastatic to the breast.
    Gynecol Oncol, 102(2): 386-90. [Abstract] [Full-text]
15. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Gynecol Oncol, 102(2): 292-9. [Abstract] [Full-text]
16. Radiation therapy after mastectomy between 1991 and 1999 in elderly women: response to clinical trial information.
    J Clin Oncol, 24(21): 3474-82. [Abstract] [Full-text]
17. Lifestyle intervention development study to improve physical function in older adults with cancer: outcomes from Project LEAD.
    J Clin Oncol, 24(21): 3465-73. [Abstract] [Full-text]
18. Multicentric breast cancer: a new indication for sentinel node biopsy--a multi-institutional validation study.
    J Clin Oncol, 24(21): 3374-80. [Abstract] [Full-text]
19. Conservation surgery for breast cancer as the preferred choice: a prospective analysis.
    J Clin Oncol, 24(21): 3367-73. [Abstract] [Full-text]
20. Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk.
    J Natl Cancer Inst, 98(14): 1014-8. [Abstract] [Full-text]
21. Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group.
    J Clin Oncol, 24(21): 3361-6. [Abstract] [Full-text]
22. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
    J Clin Oncol, 24(21): 3381-7. [Abstract] [Full-text]
23. Bromine- and iodine-substituted 16alpha,17alpha-dioxolane progestins for breast tumor imaging and radiotherapy: synthesis and receptor binding affinity.
    J Med Chem, 49(15): 4737-44. [Abstract] [Full-text]
24. Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer.
    Oncogene, 25(31): 4361-9. [Abstract] [Full-text]
25. Biomarkers, fatigue, sleep, and depressive symptoms in women with breast cancer: a pilot study.
    Oncol Nurs Forum, 33(4): 775-83. [Abstract] [Full-text]
26. Filipino American women's perceptions and experiences with breast cancer screening.
    Oncol Nurs Forum, 33(4): E71-8. [Abstract] [Full-text]
27. Studying delays in breast cancer diagnosis and treatment: critical realism as a new foundation for inquiry.
    Oncol Nurs Forum, 33(4): E62-70. [Abstract] [Full-text]
28. Increased breast calcifications in women with ESRD on dialysis: implications for breast cancer screening.
    Am J Kidney Dis, 48(2): 301-6. [Abstract] [Full-text]
29. Specimen radiography in confirmation of MRI-guided needle localization and surgical excision of breast lesions.
    AJR Am J Roentgenol, 187(2): 339-44. [Abstract] [Full-text]
30. High-spatial-resolution MRI of non-masslike breast lesions: interpretation model based on BI-RADS MRI descriptors.
    AJR Am J Roentgenol, 187(2): 330-7. [Abstract] [Full-text]
31. Comparison of MDCT and MRI for evaluating the intraductal component of breast cancer.
    AJR Am J Roentgenol, 187(2): 322-9. [Abstract] [Full-text]
32. Breast MRI using the VIBE sequence: clustered ring enhancement in the differential diagnosis of lesions showing non-masslike enhancement.
    AJR Am J Roentgenol, 187(2): 313-21. [Abstract] [Full-text]
33. MRI evaluation of small hepatic lesions in women with breast cancer.
    AJR Am J Roentgenol, 187(2): 307-12. [Abstract] [Full-text]
34. Correlation between numeric gadolinium-enhanced dynamic MRI ratios and prognostic factors and histologic type of breast carcinoma.
    AJR Am J Roentgenol, 187(2): 297-306. [Abstract] [Full-text]
35. BI-RADS-MRI: a primer.
    AJR Am J Roentgenol, 187(2): W152-60. [Abstract] [Full-text]
36. The adjacent vessel on dynamic contrast-enhanced breast MRI.
    AJR Am J Roentgenol, 187(2): W147-51. [Abstract] [Full-text]
37. Safety and feasibility of breast conserving therapy in Indian women: two decades of experience at Tata Memorial Hospital.
    J Surg Oncol, 94(2): 105-13. [Abstract] [Full-text]
38. Metastatic melanoma in the breast: a report of 27 cases.
    J Surg Oncol, 94(2): 101-4. [Abstract] [Full-text]
39. Needle-wire-guided breast tumor excision.
    J Surg Oncol, 94(2): 165-6. [Abstract] [Full-text]
40. The roles of citizenship status, acculturation, and health insurance in breast and cervical cancer screening among immigrant women.
    Med Care, 44(8): 788-92. [Abstract] [Full-text]
41. Heat fixation of cancer cells ablated with high-intensity-focused ultrasound in patients with breast cancer.
    Am J Surg, 192(2): 179-84. [Abstract] [Full-text]
42. The value of magnetic resonance imaging in diagnosis and size assessment of in situ and small invasive breast carcinoma.
    Am J Surg, 192(2): 172-8. [Abstract] [Full-text]
43. Phyllodes tumors of the breast: a case series of 106 patients.
    Am J Surg, 192(2): 141-7. [Abstract] [Full-text]
44. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
    Arch Intern Med, 166(14): 1483-9. [Abstract] [Full-text]
45. Use of the extended V-Y latissimus dorsi myocutaneous flap for chest wall reconstruction in locally advanced breast cancer.
    Ann Thorac Surg, 82(2): 752-5. [Abstract] [Full-text]
46. Long-term risk of false-positive screening results and subsequent biopsy as a function of mammography use.
    Radiology, 240(2): 335-42. [Abstract] [Full-text]
47. MR imaging-guided breast localization system with medial or lateral access.
    Radiology, 240(2): 369-79. [Abstract] [Full-text]
48. Skin-sparing mastectomy and immediate breast reconstruction by use of implants: an assessment of risk factors for complications and cancer control in 120 patients.
    Plast Reconstr Surg, 118(2): 321-30; discussion 331-2. [Abstract] [Full-text]
49. The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy.
    Expert Opin Pharmacother, 7(12): 1653-8. [Abstract] [Full-text]
50. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.
    Expert Opin Pharmacother, 7(12): 1617-25. [Abstract] [Full-text]
51. Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer.
    Clin Chem, 52(8): 1480-5. [Abstract] [Full-text]
52. Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer.
    Clin Chem, 52(8): 1510-5. [Abstract] [Full-text]
53. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer.
    J Clin Oncol, 24(22): 3672-7. [Abstract] [Full-text]
54. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
    J Clin Oncol, 24(22): 3623-8. [Abstract] [Full-text]
55. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel.
    J Clin Oncol, 24(22): 3619-22. [Abstract] [Full-text]
56. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support.
    J Clin Oncol, 24(22): 3611-8. [Abstract] [Full-text]
57. Enhanced prolidase activity and decreased collagen content in breast cancer tissue.
    Int J Exp Pathol, 87(4): 289-96. [Abstract] [Full-text]
58. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    J Clin Oncol, 24(22): 3629-35. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.